Mendel vs Triomics
Two chart abstraction platforms with real technical arguments, split by scope. Mendel is disease agnostic and makes the sharper architectural claim, pairing language models with symbolic reasoning over a clinical hypergraph precisely because generation alone produces confident errors in abstraction, and it can run inside the customer's own environment. Triomics is oncology only and better evidenced for it, with peer reviewed validation in a recognised journal, every match traced back to the pathology and biomarker behind it, and the deepest workflow integration in the trials category. For a cancer centre where oncology is the research programme, Triomics does the harder version of the job and shows its working. For an academic centre running research across specialties, or one that cannot let records leave its environment, Mendel is the more flexible platform.
- The architecture is deliberately hybrid, pairing language models with symbolic reasoning over a clinical hypergraph because generation alone produces confident abstraction errors.
- It can be hosted inside the customer's own environment, which is the strongest residency position among the trial and abstraction vendors here.
- The capability serves chart review, cohort building and observational research as well as prescreening, so one platform covers several research functions.
- It is oncology tuned rather than disease agnostic, and oncology eligibility is where the reasoning is hardest because the decisive detail sits in pathology and biomarker text.
- Peer reviewed validation in a recognised digital medicine journal is the strongest evidence position in the trials category.
- Every match is traced back to the pathology, biomarker and note that produced it, and the output lands where the oncology team already works.
Side by Side
| Axis | M Mendel |
T Triomics |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both read the whole chart to answer specific clinical questions, so the failure that matters is the eligible patient who never surfaced rather than a fabricated one, and neither publishes a false negative rate for eligibility screening. Neither publishes a security attestation or a trust centre.
Trial and cohort work also inherits documentation bias: patients with sparse or fragmented records are systematically less likely to be found, and that population overlaps with the one research already under enrols. Neither publishes pricing, though both frame the economics against the cost of clinician chart review, which is the right comparison to test against your own abstraction costs.